Biotech entity

Recombinant Albumin

Product

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Dyadic, the most common co-covered peer. Each carries 5 original sources on average. We currently track 1 Biotech story that mention Recombinant Albumin, all published on March 26, 2026.

Last mentioned: Mar 26, 2026

RSS updates
Share

Entity pulse

Recent coverage · Recombinant Albumin

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Recombinant Albumin

Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Dyadic, the most common co-covered peer. Each carries 5 original sources on average. We currently track 1 Biotech story that mention Recombinant Albumin, all published on March 26, 2026.

Stories tracked
1
Sources per story
5

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Recombinant Albumin. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q1 Guidance

    Precigen forecasts $18M+ revenue for Q1 2026, a massive sequential jump.

  2. Albumin Commercialization

    Dyadic and ProLiant Health launch recombinant albumin for global sales.

  3. FY 2025 Close

    Dyadic ends year with $8.6M cash; Paysign hits record $82M annual revenue.

  4. Papzimius Launch

    Precigen initiates commercial shipments of Papzimius for adult RRP.

Stories mentioning Recombinant Albumin 1

Pharma Positive

Commercial Inflection: Dyadic and Precigen Pivot to Product-Driven Revenue

Dyadic and Precigen have successfully transitioned from R&D-focused entities to commercial-stage biotechs, marked by the launch of recombinant albumin and Papzimius respectively. This shift is supported by a robust pharma services sector, as evidenced by Paysign’s record growth in patient affordability programs for top-tier manufacturers.

5 sources

Recombinant Albumin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.